Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: siogtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2022 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |
| 2/1/2022 | $6.00 → $1.00 | Outperform → Market Perform | SVB Leerink |
| 10/21/2021 | $8.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/12/2021 | $7.00 → $6.00 | Outperform | SVB Leerink |
| 7/12/2021 | $12.50 | Buy | Chardan Capital Markets |
Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres
- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
3 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
4 - Sio Gene Therapies Inc. (0001636050) (Issuer)
HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $7.00 from $10.00 previously
SVB Leerink downgraded Sio Gene Therapies from Outperform to Market Perform and set a new price target of $1.00 from $6.00 previously
HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $10.00 from $8.00 previously
SVB Leerink reiterated coverage of Sio Gene Therapies with a rating of Outperform and set a new price target of $6.00 from $7.00 previously
Chardan Capital Markets resumed coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $12.50
BTIG initiated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00
H.C. Wainwright reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. initiated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00
15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)
EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)
POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)
S-8 POS - Sio Gene Therapies Inc. (0001636050) (Filer)
25-NSE - Sio Gene Therapies Inc. (0001636050) (Subject)
25 - Sio Gene Therapies Inc. (0001636050) (Filer)
8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
DEFA14A - Sio Gene Therapies Inc. (0001636050) (Filer)
8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
DEFM14A - Sio Gene Therapies Inc. (0001636050) (Filer)
SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)
SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th
– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period – $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti
- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong cash position with $49.86 million of cash and cash equivalents as of September 30, 2022, expected to provide cash runway beyond December 2023 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal second quarter ended September 30, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination of the licenses to our three clini
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022. "Our financial results show the beneficial effects on operating expenses and cash resulting from the termination of the licenses to our three clinical-stage programs and the significant headcount reduction initiated in April. The winddown process of these programs will soon be concluded but the process will continue as we reduce our real estate footprint.
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022, research and development expenses were $12.6 million, an increase of $4.4 million compared to the prior year quarter. The current period increase was primarily related to increased AXO-AAV-GM1 clinical trial material manufacturing expenses. General and administrative expenses for the fourth fiscal quarter ended March 31, 2022 were $0.5 million, a decrease of $3.5 million compared to the prior year quarter. $
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value-Company had cash and cash equivalents of approximately $64 million at March 31, 2022; license termination and related headcount reduction lowers operating expenses significantly NEW YORK and DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that it has provided the required notice to the University of Massachusetts to terminate its licensing agreement to develop and commercialize gene therapy product can
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9 million of cash and cash equivalents as of December 31, 2021, providing expected cash runway into calendar H2 2023 beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 and AXO-AAV-GM2 gene therapy programs NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided corporate upd
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license agreement with Oxford Biomedica for Parkinson's disease – Portfolio prioritization allows company to focus resources and extends estimated cash runway into the second half of 2023 – David Nassif, current CFO and General Counsel of Sio, appointed interim CEO following resignation of current CEO and Board Director Dr. Pavan Cheruvu NEW YORK and DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-st
– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Granted Fast Track Designation for both AXO-AAV-GM1 and AXO-AAV-GM2 for the treatment of GM1 gangliosidosis and Tay-Sachs/Sandhoff disease – Three AXO-Lenti-PD GMP campaigns successfully completed fill and finish, achieving target titers using suspension-based manufacturing process; on-track to complete certification of clinical trial material in Q4 2021 – $101.7 million of cash and cash equivalents as of September 30, 2021, providing cash runway into calendar Q4 2022 NEW YORK and DURHAM, N.